Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-25-000046
Filing Date
2025-05-06
Accepted
2025-05-06 16:03:48
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20250331.htm   iXBRL 10-Q 1131238
2 EX-31.1 exhibit311q12025.htm EX-31.1 17230
3 EX-31.2 exhibit312q12025.htm EX-31.2 17111
4 EX-32.1 exhibit321q12025.htm EX-32.1 9843
  Complete submission text file 0001664710-25-000046.txt   5138267

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20250331.xsd EX-101.SCH 35478
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20250331_cal.xml EX-101.CAL 50614
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20250331_def.xml EX-101.DEF 190427
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20250331_lab.xml EX-101.LAB 507097
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20250331_pre.xml EX-101.PRE 341467
68 EXTRACTED XBRL INSTANCE DOCUMENT kros-20250331_htm.xml XML 429611
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 25917142
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)